Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approach—perspectives from the International Progressive MS Alliance

Author:

Zaratin Paola1ORCID,Banwell Brenda2,Coetzee Timothy3ORCID,Comi Giancarlo45,Feinstein Anthony6ORCID,Hyde Robert7,Salvetti Marco89ORCID,Smith Kathryn10ORCID

Affiliation:

1. Italian Multiple Sclerosis Foundation, Genoa, Italy

2. Division of Child Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

3. National Multiple Sclerosis Society, New York, NY, USA

4. Università Vita Salute San Raffaele, Milan, Italy

5. Casa di Cura del Policlinico, Milan, Italy

6. Sunnybrook Research Institute and University of Toronto, Toronto, Canada

7. Biogen International GMBH, International Progressive MS Alliance Industry Forum representative, Zürich, Switzerland

8. Department of Neurosciences, Mental Health and Sensory Organs, Centre for Experimental Neurological Therapies (CENTERS), Sapienza University of Rome, Rome, Italy

9. Istituto Neurologico Mediterraneo (INM) Neuromed, Pozzilli, Italy

10. International Progressive MS Alliance, Lyme, CT, USA

Abstract

Background The COVID-19 pandemic has reinforced the importance of research for the health of our society and highlighted the need for stakeholders of the health research and care continuum to form a collaborative and interdependent ecosystem. Objective With the world still reeling from waves of the COVID-19 pandemic and adapting to the vaccine rollout at widely different rates, the International Progressive MS Alliance (hereafter Alliance) organized a meeting (April 2021) to consider how the Covid-19 pandemic impacts the health and well-being of people with progressive Multiple Sclerosis (MS). Methods We invited the Alliance stakeholders and experts to present what they have learned about SARS-CoV-2 infection and progressive MS and to define future scientific priorities. Results The meeting highlighted three priorities for additional focus: (1) the impact of Disease Modifying Therapies (DMTs) on the risk of COVID-19 and on the efficacy of COVID-19 vaccines in people with progressive MS; (2) the long-term impact of COVID-19 and COVID-19 vaccines on the biology of progressive MS; and (3) the impact on well-being of people with progressive MS. Conclusion This paper's calls to action could represent a path toward a shared research agenda. Multi-stakeholder and long-term investigations will be required to drive and evolve such an agenda.

Publisher

SAGE Publications

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3